Duration of menopausal hot flushes and associated risk factors.

Obstet Gynecol

From the Department of Obstetrics/Gynecology, the Center for Clinical Epidemiology and Biostatistics, and the Center for Research in Reproduction and Women's Health, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and the Division of Biostatistics, Department of Medicine, Indiana University, Indianapolis, Indiana.

Published: May 2011

Objective: To estimate the duration of moderate-to-severe menopausal hot flushes and identify potential risk factors for hot flush duration.

Methods: The Penn Ovarian Aging Study cohort was monitored for 13 years. Hot flushes were evaluated at 9-month to 12-month intervals through in-person interviews. The primary outcome was the duration of moderate-to-severe hot flushes estimated by survival analysis (n=259). Potential risk factors included menopausal stage, age, race, reproductive hormone levels, body mass index (BMI), and current smoking. A secondary analysis included women who reported any hot flushes (n=349).

Results: The median duration of moderate-to-severe hot flushes was 10.2 years and was strongly associated with menopausal stage at onset. Hot flushes that started near entry into the menopause transition had a median duration greater than 11.57 years; onset in the early transition stage had a median duration of 7.35 years (95% confidence interval [CI] 4.94-8.89; P<.001); and onset in the late transition to postmenopausal stages had a median duration of 3.84 years (95% CI 1.77-5.52; P<.001). The most common ages at onset of moderate-to-severe hot flushes were 45-49 years (median duration, 8.1 years; 95% CI 5.12-9.28). African American women had a longer duration of hot flushes than white women in adjusted analysis.

Conclusion: The median duration of hot flushes considerably exceeded the timeframe that is generally accepted in clinical practice. The identified risk factors, particularly menopausal stage, race, and BMI, are important to consider in individualizing treatment and evaluating the risk-to-benefit ratio of hormones and other therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085137PMC
http://dx.doi.org/10.1097/AOG.0b013e318214f0deDOI Listing

Publication Analysis

Top Keywords

hot flushes
28
risk factors
12
duration moderate-to-severe
12
median duration
12
hot
8
menopausal hot
8
potential risk
8
moderate-to-severe hot
8
menopausal stage
8
flushes
7

Similar Publications

Risk Factors for Treatment Toxicity and High Side Effect Burden Among Breast Cancer Survivors: A Retrospective Chart Review.

Cancers (Basel)

January 2025

Department of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.

Background/objectives: This study describes the sequelae, side effects, and toxicities experienced by Canadian breast cancer survivors at a breast cancer survivorship clinic at a tertiary academic cancer centre and identifies potential risk factors which may be associated with increased side effect burden.

Methods: A retrospective chart review was performed of adult patients treated at the Sunnybrook Breast Cancer Survivorship Clinic from 6 July 2022, to 30 September 2023 ( = 435).

Results: Most patients (72.

View Article and Find Full Text PDF

Background/objectives: Breast cancer survivors undergoing long-term endocrine therapy often experience multiple symptoms, including pain, fatigue, sleep disturbance, hot flashes, anxiety, and depression. This study explored the feasibility and acceptability of integrating acupuncture for symptom management in medically underserved breast cancer survivors.

Methods: This randomized controlled trial was conducted at two clinics serving medically underserved populations.

View Article and Find Full Text PDF

Background: Postmenopausal women are more likely to experience vasomotor symptoms (VMS), such as heat sensation and sweating. Recent trials have investigated fezolinetant in the treatment of VMS in postmenopausal women. Our study aims to conduct a meta-analysis of these trials in order to estimate fezolinetant's effectiveness and safety in the management of VMS in postmenopausal women.

View Article and Find Full Text PDF

Context: Breast cancer poses significant challenges due to its high incidence and prevalence, necessitating heightened attention. Understanding how patients prioritize different treatment options based on various attributes can assist healthcare decision-makers in maximizing patient utility. The discrete choice experiment, a conjoint method, facilitates preference elicitation by presenting different attributes and choices.

View Article and Find Full Text PDF

Hormone replacement therapy (HRT) used to treat hot flashes has side effects, such as an increased risk of coronary heart disease and breast cancer. There are ongoing controversies regarding the risk of ovarian cancer associated with HRT. HRT is best avoided in conditions such as liver or gallbladder disease and gastrointestinal disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!